Trying to figure out what to do with BNP Paribas stock right now? You are not alone. The rollercoaster of recent price swings can seem dizzying, but that volatility is exactly what has caught the ...

BNP Paribas (ENXTPA:BNP) posted revenue growth of 7.2% per year, outpacing the French market's 5.5% average, while earnings averaged 9.4% annual growth over the past five years. However, the most ...

BNP Paribas BNP recently reported solid results, reaffirming its bullish guidance for top-line growth and confirming a EUR 5 billion (7% of its current market value) share buyback. After incorporating ...

Dallas, TX - More utility for a rapid assay for B-natriuretic peptide (BNP) has been reported in two studies published this month. In one, which appears in the February 5, 2002 issue of Circulation, ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Addition of soluble urokinase-type plasminogen activator receptor levels to models including B-type natriuretic peptide may improve their prognostic value for patients with HF, researchers reported.

Solid Q1 results and 2025 objectives confirmed. BNP recorded a low level of risk throughout the cycle. Expected growth in DPS and buyback (supportive news from ECB). Our buy rating is then confirmed.

Strong growth in all BNP divisions. Low cost of risk (even considering the negative one-off from Poland). Solid CET1 ratio and strong ROTE results. Based on tangible book value evolution, we slightly ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...